- Flechon A, Biron P, Droz J. High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience. Int J Cancer. 1999;83:844-7 pubmed..A European randomized trial, which studies the role of HDCT in the first-line salvage treatment of non-refractory disease, is ongoing. So far, HDCT is not a standard treatment of GCT. ..
- Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 t. Ann Oncol. 2011;22:2476-81 pubmed publisher..The median follow-up was 9.3 months [95% confidence interval (CI) 0.2-27.1] and the median overall survival 9.6 months (95% CI 8.7-12.7). The benefit-risk ratio of this regimen seems unfavorable due to poor response and high toxicity. ..
- Flechon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz J. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int. 2010;106:779-85 pubmed publisher....